Buscar
12/05/2026
Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios
Mondésert, E, Cristol, JP, Bargnoux, AS, Duchiron, M, Busto, GU, Hirtz, C, Barnier-Figue, G, Perrein, F, Turpinat, C, Jurici, S, Gabelle, A, Bennys, K, Lehmann, S, Delaby, C. Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios. NEUROLOGY. 2026; 106(9)DOI:10.1212/WNL.0000000000214931. PMID:41980230. IF:8.500(Q1/1D).
12/05/2026
Contribution of hospitals and clinical services to global warming: a scoping systematic review
Merino-Urrutia, W, Cárcamo-Fuentes, C, Peña, M, Zalej-Rakela, B, Rodríguez-García, J, Gottschalk-Cuevas, MD, Rubilar-Rocha, F, Martínez-Zapata, MJ. Contribution of hospitals and clinical services to global warming: a scoping systematic review. Frontiers in Public Health. 2026; 14DOI:10.3389/fpubh.2026.1778269. PMID:42205444. IF:3.400(Q1/2D).
07/05/2026
The role of Spanish clinical pharmacologists in economic evaluations of health technologies
Delgado-Espinoza, CE, Antonijoan, RM, Martínez-Zapata, MJ. The role of Spanish clinical pharmacologists in economic evaluations of health technologies. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 82(6)DOI:10.1007/s00228-026-04070-2. PMID:42091708. IF:2.700(Q2/5D).
07/05/2026
Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials
Padilla-Lopez, M, Manicone, F, Holle, SLD, Wenzl, FA, Kimmoun, A, Mebazaa, A, Sionis, A. Novel treatment strategies in cardiogenic shock: an update on ongoing clinical trials. HEART FAILURE REVIEWS. 2026; 31(1)DOI:10.1007/s10741-026-10637-z. PMID:42095992. IF:4.200(Q1/3D).
04/05/2026
Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance
Barguilla, A, Riera, P, Ros-Castelló, V, Muino, E, Sierra-Marcos, A. Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance. Expert Review of Neurotherapeutics. 2026; 26(5)DOI:10.1080/14737175.2026.2647028. PMID:41875007. IF:3.400(Q2/3D).
04/05/2026
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregón, M, Campos, B, Coves, J, de Castro, J, Domènech, M, Dómine, M, Campelo, RG, Lucía-Gozálvez, C, Lázaro-Quintela, M, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares-Hernández, A, Reguart, N, Sala, MA, Medina, K, Vila, L, Massutí, B. ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY. 2026; 26(5)DOI:10.1080/14712598.2026.2677905. PMID:42159280. IF:4.000(Q2/3D).
04/05/2026
Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort
Fernandez-Camins, B, Vlacho, B, Rojo-López, MI, Granado-Casas, M, Gratacòs, M, Ortega-Bravo, M, Cendros-Massioui, M, Palmieri, F, Perera-LLuna, A, Franch-Nadal, J, Mauricio, D. Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort. Cardiovascular Diabetology. 2026; 25(1)DOI:10.1186/s12933-026-03198-w. PMID:42083025. IF:10.600(Q1/1D).
03/05/2026
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer
Cella, L, Finocchiaro, A, Slusarczyk, A, Krajewski, W, Velasco, JC, Subiela, JD, Claps, F, Grobet-Jeandin, E, Del Giudice, F, Gallioli, A, Laukhtina, E, Marcq, G, Mari, A, Afferi, L, Albisinni, S, Soria, F, Hurle, R, Paciotti, M, Ferro, M, Perdonà, S, Mertens, LS, Moschini, M, Pradere, B, Contieri, R. Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. Future Oncology. 2026; 22(11)DOI:10.1080/14796694.2026.2661768. PMID:42041162. IF:2.600(Q3/6D).